In one line
Pregnancy is an immunological and physiological state that converts an ordinary respiratory or emerging viral infection into a potentially lethal one, so the consultant task is to recognise the pregnant woman as a high-risk host, treat aggressively and early, vaccinate proactively, and refuse to let the historical reflex of excluding pregnant women from trials and treatment leave them unprotected in the next outbreak.
Mechanism & pathophysiology
The pregnant woman is not simply a non-pregnant patient who happens to be carrying a fetus; she is a different host, and three coupled changes explain why she fares worse with respiratory and emerging infection.
The first is immunological. To tolerate a semi-allogeneic fetus, maternal adaptive immunity is remodelled rather than suppressed — a shift in the T-helper balance away from Th1 cell-mediated responses towards Th2 and regulatory phenotypes, with altered natural-killer-cell and complement regulation at the maternal–fetal interface. That remodelling is protective of the pregnancy but blunts the containment of intracellular pathogens, viruses among them. It is the reason influenza, varicella, hepatitis E and a string of emerging viruses behave more aggressively in pregnancy than the same virus in the same woman a year before or after. It is not global immunodeficiency — the febrile, antibody-producing machinery still works — but it is a measurable tilt that widens the window in which a virus can establish and disseminate before it is controlled.
The second is respiratory mechanics and oxygen economics. The gravid uterus splints the diaphragm and reduces functional residual capacity by roughly a fifth at term, so the oxygen reservoir that buffers a sick adult through an apnoea or a deteriorating pneumonia is already spent. Simultaneously, oxygen consumption rises by 20% or more to supply the fetoplacental unit and the increased maternal metabolic rate. A mother therefore starts any respiratory insult with a smaller reserve and a higher demand — she desaturates faster, tolerates less, and decompensates with a steepness that catches teams accustomed to the resilience of young non-pregnant adults. Compensatory respiratory alkalosis is the physiological baseline of pregnancy, so a "normal" or rising carbon dioxide in a breathless gravid woman signals exhaustion, not stability.
The third is the procoagulant state. Pregnancy is a physiological hypercoagulable condition — raised fibrinogen and factors VIII, IX and X, reduced protein S, acquired activated-protein-C resistance and impaired fibrinolysis — evolved to limit postpartum haemorrhage. Layered onto an infection that itself activates coagulation through endothelial injury and inflammation, this baseline tips towards thrombosis. COVID-19 made the point unmistakable: the disease is as much a thrombo-inflammatory endotheliopathy as a pneumonia, and pregnancy supplies the second hit. Venous thromboembolism, placental thrombotic pathology, and the microvascular injury that drives a pre-eclampsia-like picture all follow from the same convergence.
A fourth axis is the placenta itself as a target organ, and it explains why some emerging infections injure the fetus out of all proportion to maternal illness. The placenta is both a barrier and a route. For most respiratory viruses, including SARS-CoV-2, it is a competent barrier — direct fetal infection is rare, and the fetal harm is overwhelmingly indirect, mediated through maternal hypoxia, high fever (itself teratogenic in the first trimester and a driver of preterm labour later), placental thrombotic and inflammatory injury, and iatrogenic preterm delivery of a sick mother. For a smaller group of pathogens the placenta is permissive and the virus is directly neurotropic or fetotropic: Zika crosses and targets neural progenitor cells, cytomegalovirus and rubella cross and disseminate, and the consequence is a congenital syndrome rather than a maternal pneumonia. Reading where a new pathogen sits on this barrier-versus-route spectrum — does it threaten the mother, the fetus, or both, and by what mechanism — is the single most useful early question, because it dictates whether the clinical priority is maternal resuscitation, fetal surveillance and counselling, or both at once.
These mechanisms are general, and that generality is the point. Whatever the next novel pathogen is, the pregnant host will tend to present late (her warning signs disguised by the normal physiology of pregnancy — a resting tachycardia, a raised respiratory rate, a lower baseline blood pressure all read as "pregnant"), progress fast (small reserve, high demand), and thrombose. Pandemic preparedness in obstetrics is therefore a structural discipline, not a disease-specific one: the lesson of one outbreak is the template for the next, and a maternity service that has thought through surge triage, oxygen logistics, antiviral and corticosteroid protocols, thromboprophylaxis, infection prevention and the ethics of including pregnant women is ready for a pathogen it has never seen. The outbreaks that built the modern obstetric understanding of this host form a coherent lineage rather than a list: the 1918 H1N1 and 1957 H2N2 influenza pandemics first quantified the excess maternal mortality; the 2009 H1N1 pandemic re-proved it in the modern era and established early antiviral treatment; the 2015–16 Zika epidemic redefined what mild maternal illness can do to a fetus; the West African Ebola outbreak exposed the lethal combination of a haemorrhagic infection and a haemorrhage-prone organ; and SARS-CoV-2 from 2020 assembled, in real time, the cleanest evidence base and the sharpest ethical argument the field has. Each taught a transferable rule, and a consultant who can recite the rules can manage the next pathogen on the morning it arrives.
Assessment
The first move with any unwell pregnant woman in an outbreak is to assume the pregnancy is amplifying the illness and to stage her against that expectation rather than against a non-pregnant baseline.
- Recognise the camouflaged deterioration. Use an obstetric early-warning chart (MEOWS) with pregnancy-adjusted trigger thresholds; the single most sensitive sign of a deteriorating respiratory infection is a rising respiratory rate, which is also the sign most often dismissed because tachypnoea is mild and the woman looks deceptively well. A respiratory rate above 20–22 sustained, any new oxygen requirement, or a saturation below 94% on air in a pregnant woman with a respiratory virus is a regional/tertiary-referral trigger, not a watch-and-wait.
- Quantify reserve, not just the snapshot. Oxygen saturation, respiratory rate, work of breathing and trend over hours; a venous or arterial blood gas where available — a normalising or rising carbon dioxide in a tachypnoeic woman is impending failure. Lactate, full blood count, renal and liver function, and coagulation including D-dimer (interpreted against the elevated pregnancy reference range, not the non-pregnant cut-off).
- Establish the pathogen and the differential. Targeted molecular testing (SARS-CoV-2, influenza A/B PCR, respiratory viral panel where available); chest imaging should not be withheld for pregnancy — a chest radiograph delivers a negligible fetal dose and CT pulmonary angiography is justified when pulmonary embolism is a real possibility, because a missed maternal PE is the greater harm. In an emerging-disease context, take a structured exposure and travel history and notify according to the national outbreak case definition early; in South Africa the National Institute for Communicable Diseases is the route for novel-pathogen confirmation and reporting.
- Stage the host's modifiers — the SA layer. HIV status and, if positive, CD4 count and viral suppression; tuberculosis co-infection; anaemia; diabetes; gestation and fetal wellbeing. An immunosuppressed mother may not mount the fever and leucocytosis that would otherwise flag severe infection, so a blunted inflammatory picture in an unwell low-CD4 woman is a reason for more concern, not reassurance, and lowers the threshold for escalation.
- Assess the fetus as a second patient, separately. Maternal hypoxia and high fever both threaten the fetus; continuous monitoring at viable gestations, a steroid and magnesium plan if preterm delivery becomes likely, and a clear understanding that fetal compromise can be the first visible sign of maternal decompensation — but that stabilising the mother almost always comes before delivering the fetus, because a hypoxic mother cannot be rescued by emptying the uterus.